Following reports that 30 people died in Norway after receiving the Pfizer vaccine, the government, its health officers and Pfizer have all been falling over themselves, assuring us the vaccine is safe.
Notwithstanding these assurances, it is imperative that safety concerns be addressed in detail. Professor Paolo Bellavite, of the University of Verona Medical School, whose expertise is in experimental medicine and innate immunity, argues that the Pfizer vaccine clinical trials concluded far too soon.
Already a subscriber? Log in
Get 10 issues
for $10
Subscribe to The Spectator Australia today for the next 10 magazine issues, plus full online access, for just $10.
- Delivery of the weekly magazine
- Unlimited access to spectator.com.au and app
- Spectator podcasts and newsletters
- Full access to spectator.co.uk
Comments
Don't miss out
Join the conversation with other Spectator Australia readers. Subscribe to leave a comment.
SUBSCRIBEAlready a subscriber? Log in